Axovant's stock is crashing after failing a key drug trial

Shares of Axovant are plummeting after the company had failed a key late-stage trial for its Alzheimer’s drug.

Shares are down 75.59% in early trading on Tuesday at $US5.92 a piece. Axovant closed Monday’s trading session at $US24.25.

The pharmaceutical company, founded by 32-year-old Vivek Ramaswamy, was trading for just a tenth of its previous day’s value at one point Tuesday morning.

Axovant is the latest company to fail a notoriously hard Alzheimer’s drug trial. Drugs hoping to treat the disease or its symptoms have failed to pass clinical trials 99% of the time.

Axovant’s drug, intepirdine, hoped to stop the decline of cognitive function and ability to perform daily tasks in those with Alzheimer’s. The company combined intepirdine with donepezil, an existing Alzheimer’s drug, hoping to improve the effectiveness of donepezil.

The company will continue to look for other uses of its
intepirdine drug.

Shares were up 113% this year before the failed drug trial. Axovant is now down 52.18% in 2017.

Click here to watch shares of Axovant trade in real time…

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.